Jill Broadfoot

Director at Cue Biopharma.

Earliest Form D on file: May 2026

Filed May 14, 2026

Cue Biopharma

Biologics that modulate disease-specific T cells

Biotech, Boston MA

Named, Director.

$30M

sold of $30M offered

Network

At Cue Biopharma

13 people

Sumita Ray, JD
Together on 1 filing
Executive Officer, signed as Chief Legal & Compliance Officer
Shao-Lee Lin
Together on 1 filing
Executive Officer, Director
Colin Sandercock
Together on 1 filing
Executive Officer
Daniel Baker
Together on 1 filing
Executive Officer
Frank Morich
Together on 1 filing
Director
Pamela D. Garzone
Together on 1 filing
Director

7 more at Cue Biopharma